Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vanda Pharmaceuticals Inc.VNDA · Entity 5861 | Director | June 04, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vanda Pharmaceuticals Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 135,069 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 41,600 · Balance 135,069 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 4, 2027, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 4, 2027, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 8, 2026 20:17 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 41,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-261782 · ownership.xml · nonDerivative · entry 1 Honore Tage · CIK 0001967946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,069 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 4, 2027, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 21:28 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 30,000 | $8.03 | $240,900.00 |
DisclosureSEC source: 0001193125-26-067185 · ownership.xml · nonDerivative · entry 1 Honore Tage · CIK 0001967946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,469 Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 21:34 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 59,225 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083885 · ownership.xml · nonDerivative · entry 1 Honore Tage · CIK 0001967946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,469 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 5, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| May 17, 2024 Filed May 21, 2024 20:55 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (right to buy) · Derivative | 37,578 | $0.00 Strike: $5.48 | $0.00 |
DisclosureSEC source: 0000950170-24-063022 · ownership.xml · derivative · entry 2 Honore Tage · CIK 0001967946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,578 Underlying: Common Stock · 37,578 shares Expires 2034-05-16 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on May 17, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| May 17, 2024 Filed May 21, 2024 20:55 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 20,529 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-063022 · ownership.xml · nonDerivative · entry 1 Honore Tage · CIK 0001967946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,244 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 17, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:19 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (right to buy) · Derivative | 33,960 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001209191-23-036282 · doc4.xml · derivative · entry 2 Honore Tage · CIK 0001967946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,960 Underlying: Common Stock · 33,960 shares Expires 2033-06-07 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:19 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 17,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036282 · doc4.xml · nonDerivative · entry 1 Honore Tage · CIK 0001967946 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,715 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:50 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (right to buy) · Derivative | 51,276 | $0.00 Strike: $6.39 | $0.00 |
DisclosureSEC source: 0001209191-23-019714 · doc4.xml · derivative · entry 2 Honore Tage · CIK 0001967946 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,276 Underlying: Common Stock · 51,276 shares Expires 2033-03-14 F2 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on March 15, 2024, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:50 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 26,408 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-019714 · doc4.xml · nonDerivative · entry 1 Honore Tage · CIK 0001967946 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,408 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 15, 2024, provided the Reporting Person has provided continuous service through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.